Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...
This was the stock's fourth consecutive day of losses.
Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...
Stocks to Look After. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) ...
In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...
2d
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research ...
Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...
Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...
Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...
This was the stock's second consecutive day of losses.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback